Interleukin-6 inhibitor : tocilizumab

Kevin D. Pile; Garry G. Graham; Stephen M. Mahler

doi:10.1007/978-3-7643-8550-7_231

Interleukin-6 inhibitor : tocilizumab

Kevin D. Pile, Garry G. Graham, Stephen M. Mahler

Research output: Chapter in Book / Conference Paper › Chapter

Abstract

Inhibitors of interleukin-6 (IL-6) are proteins which decrease the actions of the inflammatory cytokine, IL-6. Clinically, tocilizumab is the major inhibitor of IL-6. Several other proteins with IL-6 inhibitory actions (e.g., sirukumab) are being tested in clinical trials. IL-6 inhibitors are members of a general class, biological disease-modifying anti-rheumatic drugs (bDMARDs). Unlike the conventional synthetic DMARDs (csDMARDs) which have small molecular masses, they are not classified as slow-acting anti-rheumatic drug (SAARDs) because they are considered to have more specific and rapidly developing actions.

Original language	English
Title of host publication	Compendium of Inflammatory Diseases
Editors	Michael J. Parnham
Place of Publication	Switzerland
Publisher	Springer
Pages	692-696
Number of pages	5
ISBN (Electronic)	9783764385507
ISBN (Print)	9783764385309
DOIs	https://doi.org/10.1007/978-3-7643-8550-7_231
Publication status	Published - 2016

Keywords

interleukin-6
monoclonal antibodies
cytokines

Access to Document

10.1007/978-3-7643-8550-7_231

Cite this

@inbook{6fe90ffc5ce24fdca55edc154435c598,

title = "Interleukin-6 inhibitor : tocilizumab",

abstract = "Inhibitors of interleukin-6 (IL-6) are proteins which decrease the actions of the inflammatory cytokine, IL-6. Clinically, tocilizumab is the major inhibitor of IL-6. Several other proteins with IL-6 inhibitory actions (e.g., sirukumab) are being tested in clinical trials. IL-6 inhibitors are members of a general class, biological disease-modifying anti-rheumatic drugs (bDMARDs). Unlike the conventional synthetic DMARDs (csDMARDs) which have small molecular masses, they are not classified as slow-acting anti-rheumatic drug (SAARDs) because they are considered to have more specific and rapidly developing actions.",

keywords = "interleukin-6, monoclonal antibodies, cytokines",

author = "Pile, {Kevin D.} and Graham, {Garry G.} and Mahler, {Stephen M.}",

year = "2016",

doi = "10.1007/978-3-7643-8550-7_231",

language = "English",

isbn = "9783764385309",

pages = "692--696",

editor = "Parnham, {Michael J.}",

booktitle = "Compendium of Inflammatory Diseases",

publisher = "Springer",

}

TY - CHAP

T1 - Interleukin-6 inhibitor : tocilizumab

AU - Pile, Kevin D.

AU - Graham, Garry G.

AU - Mahler, Stephen M.

PY - 2016

Y1 - 2016

N2 - Inhibitors of interleukin-6 (IL-6) are proteins which decrease the actions of the inflammatory cytokine, IL-6. Clinically, tocilizumab is the major inhibitor of IL-6. Several other proteins with IL-6 inhibitory actions (e.g., sirukumab) are being tested in clinical trials. IL-6 inhibitors are members of a general class, biological disease-modifying anti-rheumatic drugs (bDMARDs). Unlike the conventional synthetic DMARDs (csDMARDs) which have small molecular masses, they are not classified as slow-acting anti-rheumatic drug (SAARDs) because they are considered to have more specific and rapidly developing actions.

AB - Inhibitors of interleukin-6 (IL-6) are proteins which decrease the actions of the inflammatory cytokine, IL-6. Clinically, tocilizumab is the major inhibitor of IL-6. Several other proteins with IL-6 inhibitory actions (e.g., sirukumab) are being tested in clinical trials. IL-6 inhibitors are members of a general class, biological disease-modifying anti-rheumatic drugs (bDMARDs). Unlike the conventional synthetic DMARDs (csDMARDs) which have small molecular masses, they are not classified as slow-acting anti-rheumatic drug (SAARDs) because they are considered to have more specific and rapidly developing actions.

KW - interleukin-6

KW - monoclonal antibodies

KW - cytokines

UR - http://handle.westernsydney.edu.au:8081/1959.7/uws:39713

U2 - 10.1007/978-3-7643-8550-7_231

DO - 10.1007/978-3-7643-8550-7_231

M3 - Chapter

SN - 9783764385309

SP - 692

EP - 696

BT - Compendium of Inflammatory Diseases

A2 - Parnham, Michael J.

PB - Springer

CY - Switzerland

ER -

Interleukin-6 inhibitor : tocilizumab

Abstract

Keywords

Access to Document

Other files and links

Fingerprint

Cite this